Hyperkalaemia, characterised by elevated potassium levels, affects 6-7% of the global population, posing severe risks to those with chronic kidney disease. Key symptoms include shortness of breath, ...
AstraZeneca’s real-world evidence (RWE) ZORA study shows the negative consequences of reducing or discontinuing life-saving renin-angiotensin-aldosterone system inhibitor (RAASi) medication in ...
Mineralocorticoid-receptor antagonists (MRAs) reduce blood pressure and albuminuria in patients treated with angiotensin-converting-enzyme inhibitors or angiotensin-II-receptor blockers. The use of ...
In patients with type 2 diabetes mellitus (T2DM), the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduced the risk of developing a hyperkalaemia event but did not reduce ...
AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disease. The STABILIZE-CKD and ...
SURREY, UK - MONDAY 16th DECEMBER, 2019 - The National Institute for Health and Care Excellence (NICE) has published a final appraisal determination (FAD) recommending Veltassa® (patiromer) for the ...
London, UK, Monday 7 November 2022 – AstraZeneca UK today announced that the Scottish Medicines Consortium (SMC) has updated its advice for Lokelma (sodium zirconium cyclosilicate [SZC]) for adult ...
In patients with heart failure and reduced ejection fraction (HFrEF), neprilysin inhibition with sacubitril/valsartan might attenuate the increased risk of hyperkalaemia that occurs when ...
Nurses and other clinicians have been told to treat all people with high potassium levels as an emergency, after 35 people including a baby and child suffered a cardiac arrest. Subscribe today for ...
The appraisal committee considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.
Prescribing antibiotics to older patients receiving spironolactone is associated with a major increase in the risk of admission to hospital for hyperkalaemia, a BMJ study shows. A case-control study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results